

Index

a

abdominal compartment
 syndrome 178, 234
acetaldehyde 397, 398
acetylcholine 35, 41
acetylcholine receptor 906, 908, 909
acinar cell carcinoma (ACC) 963–965
acinar cell neoplasms 623
acinar cells 9, 12–21, 35–45
acinar-driven mutant protein 99
acute alcoholic pancreatitis 107, 109
acute biliary pancreatitis (ABP)
 119–125, 278–281
acute edematous pancreatitis
 211–212
acute necrotic collection (ANC)
 211–214, 216, 219, 260, 261, 288,
 289, 294, 295
acute necrotizing pancreatitis
 (ANP) 212, 213, 260, 261
acute (peri-)pancreatic fluid collection
 (APFC) 294–297
acute pancreatitis (AP) 128–133,
 138–142, 155–162, 164–168,
 170–174, 176–181, 185–188,
 191–197, 199–205, 222–227,
 238–242, 284–286, 288–291,
 294–298, 300–303, 306–312, 317,
 319, 334–341, 376
acute peripancreatic fluid collection
 (APFC) 212, 288
acute recurrent pancreatitis 196–197,
 390, 391
adaptive growth 78–80
adenocarcinoma 901, 1143, 1144,
 1147, 1150
adenosine triphosphate (ATP) 38, 42,
 44, 45
adjunctive treatments 474–477

adjuvant 1143–1150, 1291–1296
adjuvant therapy 1131, 1134
adult respiratory distress syndrome
 (ARDS) 158, 159
advance imaging, pancreatic
 lesions 372
aggressive fluid resuscitation 223–225
alcohol 107–114
alcohol/ethanol metabolism 108–110,
 112–113
alcoholic chronic pancreatitis (ACP)
 404, 406–407
alcoholic pancreatitis 107–114
alcohol misuse 396–401
allogeneic islet transplantation 1312
 α -and β -islet cells 781, 785–787
Alternative Lengthening of Telomeres
 (ALT) 772, 774, 775, 777
ampulla 1291
ampulla of Vater 10, 1254–1260,
 1264–1269
ampullary adenocarcinoma
 1244, 1245
ampullary adenoma 1254–1260
ampullary cancer 1236, 1254–1258,
 1260, 1278, 1300–1303
ampullary duodenal
 adenoma 1242–1244
ampullectomy 1272–1277
analgesics 468–471
annular pancreas 24–25, 185, 187
antibiotics 238–242
antibiotic therapy 255
antioxidants 451–457
apical calcium signals 35–39, 41–44
Appleby procedure 1103
arenchyma-sparing pancreatectomy
 (PSP) 850–853
artificial intelligence (AI) 680–686

Asian criteria 561, 562
ATM 1013, 1014
autoimmune pancreatitis (AIP)
 419–421, 535–538, 540–544, 546–552,
 568–571, 573–576, 579–592, 595–598,
 600–603, 605–607, 609–612
autonomic nervous system
autophagy 398
azathioprine 601, 606

b

bacterial infection 238–241
bariatric surgery 201
Beger procedure 498
benign pancreatic tumor 709
Berne procedure 498, 499
bile duct stone 278, 279, 281
biliary drainage 1122, 1123, 1125, 1126
biliary pain 60, 62
biliary pancreatitis 119–125, 278–281
biliary stenting 1238
biliary strictures 425, 426
biliary tree 888
biliodigestive anastomosis 1118
biliopancreatic ductal system
 variants 185
biomarkers 1189, 1193
biosimulation 607
bladder drainage 1324, 1326
bone health 442, 443
borderline resectable 1099, 1100,
 1102, 1131–1136, 1138
borderline resectable pancreatic cancer
 (BRPC) 1141, 1142
brain remodeling 463, 464
branched chain amino acids
 (BCAA) 77
BRCA 1188–1190
BRCA2 1013, 1014

C

calcitonin gene-related peptide (CGRP) 148, 149
 calcium 397
 calcium channels 36–44
 calcium sensing receptor (CaSR) 128, 132, 133
 calcium signaling 37–40, 42, 44–45
 cancer biomarkers 1221
 cancer pain 1201–1205
 cancer stem cell 907
 cancer vaccines 1166, 1167, 1169, 1174
 capillary leak syndrome (CLS) 230–234
 carbohydrate antigen (CA) 19-9 1028, 1029
 carboxypeptidase A1 (CPA1) 130–131
 carcinogenesis 986
 carcinogens 905–909
 carcinoma 1293, 1295–1296
 cationic trypsinogen (PRSS1) 128–130, 132, 133
 CD20 605
 CDKN2A 1013, 1014
 celiac plexus neurolysis 1203, 1204
 cell-free DNA (cfDNA) 1030
 cell identity 6
 cell of origin 781–784, 787, 921–926
 central nervous system (CNS) 146–148, 151
 central pancreatectomy 715
 chemokine 541–542
 chemotherapy 928–931, 1196–1199, 1291–1296
 cholangiocarcinoma 1291–1294
 cholangitis 278–281
 cholecystokinin (CCK) 35, 76–81
 cholecystokinin (CCK)1 receptor 65–68
 cholecystokinin (CCK)-releasing 876–878
 choledochal cyst 185–187
 chromogranin A (ChA) 799
 chronic alcoholic pancreatitis 107, 109, 110
 chronic inflammation 326, 330, 331
 chronic pancreatitis (CP) 88–91, 94, 317–324, 326–331, 334–341, 349–354, 357–364, 376, 390–392, 404–409, 418–421, 424–428, 430–434, 436, 439, 440, 445–449, 451–457, 460–464, 467–471, 474–477, 480–484, 486–492, 496–499, 501–504, 506–512, 515–519, 906, 909
 chronic pancreatitis treatment 464
 chymotrypsin C (CTRC) 128, 130, 131
 chymotrypsinogen C (CTRC) 379–380
 cinematic rendering (CR) 997, 998, 1007
 circulating tumor cell (CTC) 1030
 classification, neuroendocrine neoplasm 763–764
 classification, neuroendocrine tumors 753–761
 classification of acute pancreatitis 238, 239
 classification, PanNENs 891–893
 claudin 2 (CLDN2) 128, 130
 clinical history 982–987
 clinical manifestation, type 1 autoimmune pancreatitis 546–552
 clinical outcomes 1315
 clinical trial 931
 clinical variables 176, 179–180
 code systems 322
 combination immunotherapy 1164, 1166
 common bile duct 9, 10
 common bile duct stones (CBDS) 119, 121–124
 compensatory anti-inflammatory response syndrome (CARS) 155
 complications, necrotizing pancreatitis 271–273, 275
 complications, pancreatic fistulas 300–303
 computed tomography (CT) 358–359, 680–682, 684, 686
 concomitant low-risk lesions 740–741
 congenital anomalies 185–188
 congenital cysts 26
 congenital enzyme deficiency 26–27
 conservative treatment 296–297
 corticosteroids 600–602
 C-reactive protein 180
 criteria for resection 1048
 cyst 630–635
 cystic fibrosis 390, 391
 cystic fibrosis transmembrane conductance regulator (CFTR) 128, 131–132, 379, 390–393
 cystic lesions 623–625, 628
 cystic neoplasms 623–628, 630–635, 674–678, 709–713, 723–730, 737–742
 cystic pancreatic neuroendocrine tumors (PNET) 620, 723, 724

cytokine 540–543

d

Dagradi-Serio-Iacono operation 715
 DAXX/ATRX 781, 783–788
 death domain-associated protein (DAXX) genes 772, 774–778
 debridement 244–250, 262–264, 271–275
 deep learning 680–682
 δ -cell-driven hedgehog signaling 102
 determinants 171, 173
 determinants-based classification (DBC) 170–174
 diabetes mellitus 199, 200, 204, 391, 431–433, 899–902
 diabetic ketoacidosis 200–201
 diagnosis, ampulla of Vater 1254–1260
 diagnosis, autoimmune pancreatitis 568–571
 diagnosis, nonfunctioning pancreatic neuroendocrine tumor 815–819
 diagnosis, PanNENs 895
 diagnosis, pediatric acute pancreatitis 195
 diagnosis, type 2 autoimmune pancreatitis 556–557
 diagnostic laparoscopy 1035
 diet 430–434
 dietary regulation 75–76
 differential diagnosis, neuroendocrine neoplasms 768
 differentiation 5–7
 digestive enzymes 9, 12, 14
 direct endoscopic necrosectomy 248–249
 disease specific symptoms 984
 distal bile duct cancer 1235–1237, 1299–1301
 distal cholangiocarcinoma 1284–1289
 distal common bile duct carcinoma 1242–1249
 distal pancreatectomy 689–691, 732–734, 1048, 1049, 1064–1068, 1078, 1086–1088
 distal pancreatectomy with celiac artery resection (DP-CAR) 1066, 1067
 DNA damage repair 1189–1190
 DNA repair 1182
 downstaging 1131–1133, 1136, 1138
 drain 302
 drainage necrosectomy 289, 290
 drug-associated pancreatitis 202–205
 drug classification systems 200, 203
 drug rechallenge 202, 203

dual tracer scan 834
 dual X-ray absorptiometry (DXA) 442–443
 ductal adenocarcinoma 912–917
 ductal secretion 48–53
 duct cells 12, 17, 18
 duct stenting 490
 duodenal 1293–1295
 duodenal cancer 1235, 1281–1282, 1299, 1300, 1303–1305
 duodenal stenosis 425
 duodenum-preserving pancreatic head resection (DPPHR) 497, 732–735, 841–846, 849–854
 duodenum-preserving resection of the pancreatic head 345–347
 duodenum-preserving subtotal pancreatic head resection 506–512
 duodenum-preserving total pancreatic head resection 709–713
 duodenum-sparing technique 347
 DU-PAN-2 1029

e

early chronic pancreatitis 360, 362, 364, 412–416
 ectopic pancreas 24
 elective total pancreatectomy 1071, 1072
 electrophysiology 43
 endocrine-exocrine interaction 98–102
 endocrine functions 446
 endocrine insufficiency 307, 310, 1072, 1075
 endocrine pancreas 9, 19–21
 endoplasmic reticulum 36, 38–43
 endoplasmic reticulum stress 398, 401
 endoscopic and interventional treatment 486–492
 endoscopic biliary drainage 119
 endoscopic biliary stenting 1125
 endoscopic duodenal stenting 1123
 endoscopic intervention 244, 246–250
 endoscopic necrosectomy 255–257, 284–285
 endoscopic papillectomy 1264, 1265, 1267–1269
 endoscopic retrograde cholangiopancreatography (ERCP) 120–124, 195–196, 278–281, 363–364, 1122–1126, 1128, 1238, 1264, 1265
 endoscopic sphincterotomy 279
 endoscopic ultrasonography (EUS) 196, 361–363, 794, 795, 868, 1122–1128, 1237
 endoscopic ultrasound (EUS) 119, 122–123, 261, 262, 285, 366–372, 618, 619, 1014, 1264, 1265
 endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) 652–654, 688
 endoscopy 469
 endotoxemia 114
 endotoxin 108, 112
 enteral nutrition 222–227
 enteric drainage 1324, 1326
 enteropancreatic neural reflex 69
 enucleation 723–730
 enzyme secretion 35, 36, 42, 44
 epidemiology, neuroendocrine tumors 753–761
 epigenetic similarities 785–787
 ERCP papillotomy 345, 347
 ethanol 107–110, 112, 113, 396–401
 etiology, pediatric acute pancreatitis 191–194
 European Neuroendocrine Tumor Society (ENETS) 754, 756
 EUS-guided fine-needle biopsy 565
 everolimus 868, 869
 excessive hormone secretion 791
 exocrine-driven TFF2 100, 101
 exocrine function tests 352–354
 exocrine insufficiency 1071–1073, 1075
 exocrine pancreas 9, 12, 75, 76, 78, 79
 exocrine pancreatic insufficiency (EPI) 390, 391, 436–440
 extended lymphadenectomy 1099–1101
 extended surgery 1110
 external fistulas 300–303
 extracellular matrix proteins 91
 extrapancreatic cancer 611–612

f

familial adenomatous polyposis (FAP) 1235
 familial chylomicronemia syndrome (FCS) 200
 familial pancreatic cancer 951–954, 1012, 1013
 fasting test 866
 fatty acid ethyl ester (FAEE) 397, 398
 fecal microbiota transplantation 931
 ferric acid-reducing ability of plasma (FRAP) 453
 fibrosis 326–329, 331

fluid 48–50
 fluid resuscitation 222–225
 fluid secretion 35, 36, 43, 44
 FOLFIRINOX 1144, 1146, 1147, 1149, 1197, 1198
 follow-up, autoimmune pancreatitis 611
 follow-up, cystic neoplasms 744, 745, 747
 follow-up, PET 1024
 fracture 442, 443
 Frey procedure 498, 499
 functional neuroendocrine neoplasm 792, 865
 functional pancreatic neuroendocrine tumors 755
 functioning tumor 820–822, 824
 fungal infection 239, 242

g

gallbladder 888
 gallstone pancreatitis 119–121, 123, 124
 gastrectomy 872
 gastrinoma 808–812
 gastrojejunostomy 1118–1120
 GATA6 907
 gemcitabine 1144–1150, 1196–1198
 gene therapy 393
 genetically engineered mouse models (GEMMs) 781
 genetic counseling 380–381
 genetics 380, 630–633, 912–914, 916, 917
 genetic sequencing 1188
 genetic testing 380–381
 genomics 934–936, 938, 939, 1188–1192
 germline pathogenic variants 128
 glucagon-like peptide-1 (GLP-1) 801
 glucagonoma 876, 877, 879, 880
 granulocytic epithelial lesion (GEL) 546, 548, 595
 gut-lymph hypothesis 138

h

Hamburg procedure 498, 499
 HCO_3^- 48–52
 health information technology 322, 323
 hepatic metastasis 1113–1116
 hepaticojejunostomy 1118–1120
 hereditary cancer syndromes 951
 hereditary pancreatitis (HP) 375–381, 481, 483
 high-grade dysplasia (HGD) 688, 689, 691

high-grade neuroendocrine carcinomas (PanNECs) 775
 high-grade PanNET 861–862
 HISORT criteria 561, 562
 histopathology 164–168, 972, 975
 hormonal mechanisms 65–69
 hypercalcemia 199–200
 hyperlipidemia 199, 200
 hypertriglyceridemia 199–201, 203, 204
 hypoglycemia 448, 449, 865, 866, 868
 hypotension 232–234
 hypovolemia 230–232

i

idiopathic acute pancreatitis 185, 188
 idiopathic chronic pancreatitis (ICP) 383, 384, 386, 404–409
 idiopathic duct-centric pancreatitis (IDCP) 535, 536, 546, 548, 549, 551, 600, 602
 idiopathic pancreatitis 406–407
 idiosyncratic drug reaction 203
 IgG 573–576
 IgG4 535, 536, 540–543, 568–571, 573–576, 579–592
 IgG4-related disease (IgG4-RD) 546, 551, 573, 579–592, 605
 imaging, pediatric acute pancreatitis 195–196
 immune 928–931
 immune checkpoint inhibitors (ICIs) 1166, 1171
 immune complex 575, 576
 immune evasion 944
 immune responses 326
 immunohistochemistry, neuroendocrine neoplasm 768
 immunosuppression 609, 612, 1312, 1314–1319
 immunotherapy 928–931, 1164–1174, 1180, 1182–1184
 IMRT 1154, 1159
 incidence, pediatric acute pancreatitis 191
 individual susceptibility 107, 110–114
 indocyanine green fluorescence 700, 705
 infected necrosis 254–257
 infected pancreatic necrosis 170, 171, 173
 infectious complications 238–239
 inflammation 384, 385, 451, 453, 460–464, 928–930
 inflammatory bowel disease (IBD) 554–558

inflammatory mass in head of the pancreas 506, 512
 inflammatory pancreatic head mass 418–421
 insulin 75–77, 79–81
 insulinoma 808–812, 833–835, 865–869
 insulin pathway 102
 insulo-acinar portal system 98, 99
 insulo-acinar relationship 98, 99
 interleukin 8 (IL-8) 133
 internal fistulas 300–303
 International Consensus Diagnostic Criteria (ICDC) 549, 551, 554, 562–565
 International Pancreas Transplant Registry (IPTR) 1323, 1326–1330
 interoperability 322
 interstitial pancreatitis 164, 166, 168
 interventional pancreatic endoscopy 501
 interventional radiology (IVR) 829–831, 1122
 interventions for pancreatic necrosis 244–250
 intestinal injury 139–140
 intestinal ischemia 139–141
 intestinal-type adenomas 1242, 1244, 1248
 intra-abdominal hypertension 234
 intraampullary papillary-tubular neoplasm (IAPN) 1242–1245
 intracellular messengers 38, 39, 43
 intractable/refractory AIP 605
 intraductal oncocytic papillary neoplasm (IOPN) 633, 969, 974–975
 intraductal papillary mucinous neoplasm (IPMN) 617–620, 623–627, 632–633, 638–639, 666–671, 674–678, 688–691, 693, 694, 696, 697, 723–726, 737–742, 745–747, 969, 971–974, 1015
 intraductal tubulopapillary neoplasm (ITPN) 969, 974–976
 intraductal ultrasonography (IDUS) 1264, 1265
 intra-islet cross-talk 98, 100–102
 intra-islet paracrine signals 101
 intraoperative pancreatoscopy 691
 intraoperative radiation therapy (IORT) 1153, 1158–1159
 intraoperative ultrasound (IOUS) 1033, 1034
 intrathecal drug therapy 1205
 investigations, pediatric acute pancreatitis 195

Immuno tolerance 1318
 IRBIT 50–52
 islet autotransplantation 515–520
 islet cells 20, 21

j

Johanson-Blizzard syndrome 28

k

kidney failure 155
 kinases 49–52
 Ki-67 proliferation index 763, 767, 768
 KRAS 912, 913, 915–917, 1180–1182, 1184, 1188–1190, 1193

l

laboratory, autoimmune pancreatitis 568–571
 laboratory variables 176, 179–181
 lactated Ringer's solution 223–225
 laparoscopic surgery 266, 267, 269, 523, 526–531, 693–698, 1078, 1079, 1081–1088
 lavage cytology 1033, 1034
 learning curve 1093–1097
 left pancreatectomy 1063–1068
 liquid biopsy 652–663, 799
 liver 883, 885–888
 living donor pancreas transplant 1326, 1327
 local apical calcium signals 37, 39, 42–44
 local excision of periampullary lesions 1235, 1237, 1238
 local extirpation 841–846
 locally advanced pancreatic cancer 1131, 1133–1138, 1141–1142
 local recurrence 1208, 1210, 1211, 1213–1215
 long-term outcome, after acute pancreatitis 306–312
 long-term outcome, total pancreatectomy 1071–1074
 long-term results 1272–1278
 low-grade dysplasia 688
 low-grade pancreatic neuroendocrine tumors (PanNETs) 771
 low-grade PanNET 834
 low postoperative risk 509–512
 lumen-apposing metal stents (LAMS) 261–263, 285
 lymphadenectomy 833–835, 837
 lymph composition 140–141
 lymph node metastasis 1299, 1301, 1303, 1304
 lymphocytes 540–543

lymphoplasmacytic sclerosing
pancreatitis (LPSP) 535, 536, 546,
548, 549, 551, 595
lymph toxicity 141

m

machine learning 680–685
macrophages 90, 91, 94
magnetic resonance
cholangiopancreatography
(MRCP) 565, 1237, 1238
magnetic resonance imaging
(MRI) 618, 619, 680, 684, 686,
997–1009
magnetic resonance imaging/
cholangiopancreatography (MRI/
MRCP) 359–360
main pancreatic duct (MPD) 561, 565,
596–598
maintenance of pancreatic functions
710
malabsorption 351
malnutrition 431, 432
management, ampulla of Vater
1254–1260
management, pancreatic fistula
300–303
management, pediatric acute
pancreatitis 196
manometry 60–62
mature cystic teratomas 628
maturity-onset diabetes of the young
type 8 (MODY8) 98, 99
mechanistic definition 412, 413
MEN1 781–788, 834–836
mesenteric lymph 138–142
metabolism 928–930
metastasectomy 1113–1116
metastases 857–859, 861, 862
microbial-based biomarkers 928, 931
microbiome 928–931
microenvironment 928–931
microRNA 1030
microvascular network 98
middle segment resection 715–720
mild pancreatitis 164, 165, 167
minimal access retroperitoneal
pancreatic necrosectomy
(MARPN) 266–269
minimally invasive 1078–1089
minimally invasive
debridement 266–269
minimally invasive distal
pancreatectomy 1064
minimally invasive pancreatic
surgery 1064

minimally invasive surgery 693–697,
853
minimally invasive surgical
approaches 523–531
mitochondrial function 39
mixed nonneuroendocrine and
neuroendocrine neoplasms
(MiNENs) 763, 764, 767, 768
Modified Marshall Score 233
molecular pathology 971
molecular profiling 1191
molecular subtype 921, 924–926
monocyte chemoattractant protein-1
(MCP-1) 128, 133
morbidity 1071–1075
mortality 155, 157–160, 1071, 1072,
1074, 1075
MSI 1190, 1191
mTORC1 pathway 76, 77, 79, 80
MUC4 907
mucinous cystic neoplasm (MCN) 617,
620, 624–625, 639, 642, 645, 646, 649,
666–671, 688–691, 693, 694, 724, 745,
969, 976–978
mucinous neoplasm 959–962
multidetector computed tomography
(MDCT) 997–1003
multidisciplinary treatment
817–819
multimodality therapy 1213, 1215
multiparameter scoring systems
177–179, 181
multiple endocrine neoplasia
(MEN) 808–812
multiple endocrine neoplasia 1
(MEN 1) 771, 776
multiple organ dysfunction
syndrome 230, 233
multiple organ failure 233
multivisceral resection 859, 1103–1104
mumps virus 201, 202
mutations 906, 909
mycophenolate 601, 606

n

nab-paclitaxel 1197, 1198
nal-irinotecan 1197–1198
nasogastric feeding 226
nasojejunal feeding 226
natural history, cystic neoplasms
666–671
necrosectomy 247–250
necrosis 244–250, 266–269
necrosis pattern 164–168
necrotizing pancreatitis 164–167,
244–250, 254, 285

neoadjuvant chemoradiation 1141
neoadjuvant radiation therapy 1141
neoadjuvant therapy 861, 1034, 1035,
1100, 1114–1115
neoadjuvant treatment 1131–1138
neuroendocrine carcinomas
(NECs) 763–765, 767, 768, 815
neuroendocrine neoplasm
763–768, 792, 815–819, 882–888,
1248–1249
neuroendocrine neoplasm of the
pancreas (PanNEN) 841
neuroendocrine tumor (NET)
753–761, 763–768, 794–796,
815–816, 818, 872, 874
neuroendocrine tumor of the pancreas
(PanNET) 753–761, 841–846
neurogenic inflammation 462
neuroinflammation 146–151
neuropeptides 462–464
neurotransmitter acetylcholine 37
nicotine 905–909
nonampullary duodenal carcinoma
(NADC) 1248
nonfunctioning pancreatic
neuroendocrine tumor 815–819
nonfunctioning tumor 808, 810, 811
nutrition 430–434
nutritional support 222, 226

o

obesity 902
observation, PanNETs 833, 837
occult metastases 1033, 1035
olaparib 1196, 1198
oligometastases 1113, 1114, 1116
omental pouch 518
oncologic resection 688–691
open/
laparoscopic cyst-enterostomy 291
open surgery, necrotizing
pancreatitis 271–275
operative procedure 1273, 1274,
1276, 1278
opioids 1201–1205
organ-and parenchyma-sparing
surgery 715, 719
organ dysfunction 138–142
organ failure 138, 140
osteopenia 442, 443
osteopontin 907
osteoporosis 442, 443
outcomes 166, 167, 1143, 1144, 1150,
1276–1278, 1292, 1294, 1295,
1327–1330
oxidative stress 451–457

p

- pain 60–62, 334, 336, 338, 340, 341, 474–477
- pain management 451, 454, 457, 467–471
- palliation 1043
- palliative 1291–1296
- palliative pancreatectomy 1109
- pancreas 3–7, 9–21, 326–331, 630–635, 674, 675, 677, 753–761, 882–888
- pancreas cancer 1141, 1142, 1201–1205
- pancreas divisum (PD) 25, 185–186, 344–347, 409
- pancreas pathology 957–965
- pancreas surgery 523–531
- pancreas transplant alone (PTA) 1323
- pancreas transplantation 1323–1331
- pancreatectomy 700–705, 1078, 1086–1088, 1223, 1224
- pancreatic 1143–1150
- pancreatic acinar cells 397–398, 400, 401
- pancreatic adenocarcinoma 366–372, 957, 958, 998–1005, 1007, 1009, 1131, 1137
- pancreatic agenesis 23
- pancreatic anomalies 23–29
- pancreatic cancer 88, 91–94, 436, 437, 439, 480–484, 609, 611, 612, 738–742, 905–909, 921–926, 942, 943, 945, 946, 948, 982–987, 1033–1035, 1037–1043, 1047–1052, 1078–1089, 1093–1097, 1099–1104, 1113–1116, 1122–1128, 1131–1138, 1164–1174, 1180–1184, 1209–1215, 1218–1225
- pancreatic cancer recurrence 1208–1215
- pancreatic carcinoma 1021–1026
- pancreatic cell culture 79
- pancreatic cyst ablation 727–730
- pancreatic cystic lesions (PCL) 617–619
- pancreatic cystic neoplasms (PCNs) 619–621, 638–641, 654, 666, 670, 688, 693–698, 700–705, 744–747
- pancreatic cysts 642–649, 680–685, 1014–1016
- pancreatic diabetes mellitus 307, 445–449
- pancreatic drainage procedures 501–504
- pancreatic duct 48–50
- pancreatic ductal adenocarcinoma (PDAC) 666–670, 934–939, 969, 1063, 1164, 1167, 1180, 1181, 1183, 1218
- pancreatic ductal cells 398
- pancreatic ductal stones 425–426
- pancreatic enzyme replacement therapy (PERT) 430–434, 437–440, 447, 448
- pancreatic enzymes 391
- pancreatic evolution 99–100
- pancreatic exocrine 447–449
- pancreatic exocrine and endocrine function 715, 719
- pancreatic exocrine function tests 352–354
- pancreatic exocrine insufficiency (PEI) 303, 306, 445
- pancreatic fibrogenesis 86–94
- pancreatic fibrosis 461–463
- pancreatic fistula 300–303, 725–727, 730
- pancreatic fluid collections (PFC) 284, 294–298
- pancreatic function 734
- pancreatic imaging 595–598
- pancreatic intervention 254–255
- pancreatic intraepithelial neoplasia (PanIN) 969, 971, 1015
- pancreatic ischemia 462
- pancreatic islets 515, 517, 519
- pancreatic microcirculation 222–225
- pancreatic middle segment resection (PMSR) 715–720
- pancreatic necroinflammation 107, 110
- pancreatic necrosis 260–264
- pancreatic neoplasms 1055–1060
- pancreatic neuroendocrine carcinoma (PanNEC) 781
- pancreatic neuroendocrine neoplasms (PanNENs) 763–768, 891, 892
- pancreatic neuroendocrine tumor (PanNET) 781–788, 795, 796, 808–812, 820–826, 829–831
- pancreaticoduodenectomy (PD) 690, 1078–1086, 1222–1225, 1284, 1288, 1289
- pancreatic organogenesis 3–4
- pancreatic pain 460, 464, 501–504
- pancreatic protein synthesis 75–81
- pancreatic pseudocysts (PPC) 211, 212, 214, 218, 284–286, 288–290
- pancreatic regeneration 80, 81
- pancreatic resection 723–726, 729, 744, 747, 1113, 1114
- pancreatic screening 1012, 1014–1017
- pancreatic secretion 65–71
- pancreatic stellate cells (PSC) 86–94, 398–399
- pancreatic stellate cells/carcinoma-associated fibroblasts 942, 943, 945, 947–948
- pancreatic stent 1266–1268
- pancreatic strictures 424–425
- pancreatic surgery 418, 420, 421, 437, 439, 440, 501–502, 693–698, 718, 719
- pancreatic tumors 366–368, 370, 791, 794
- pancreatitis 146–151, 244–250, 266–269, 271–275, 284–286, 294–298, 326–331, 334–341, 523–531, 901
- pancreatobiliary 1242–1248
- pancreatobiliary cytology 652
- pancreatoduodenectomy (PD) 885, 1047, 1055–1060, 1281
- papillectomy 1272–1274, 1277
- parasympathetic nervous system 69
- parenchyma-preserving pancreatectomy 700, 704
- parenchyma-sparing local head resection 709–711
- parenchyma-sparing resection 694
- parenteral nutrition 222–227
- Partington 499
- pathology, neuroendocrine neoplasm 763–768
- pathology reporting 1066
- pathophysiology 168
- patterns of recurrence 1208–1210, 1213
- Pavlovian concept 71
- p16/CDKN2A 912, 913, 917
- PDX1 5–7
- Pearson syndrome 27–28
- pediatric acute pancreatitis (AP) 191–197
- pediatric pancreatic surgery 732, 734, 735
- pediatric pancreatitis 344–347
- peptic ulcer 1222
- percutaneous cyst-gastrostomy 291
- percutaneous transhepatic biliary drainage 1125
- periadventitial dissection 1057–1059
- periampullary cancer 1235–1239, 1291–1296, 1299–1305
- PET-computed tomography (PET-CT) 1021–1026
- PET diagnostics 1021–1026

PET-MRI 1021, 1024–1025
 PET staging 1021–1023, 1025, 1026
 PET tumor recurrence 1021, 1023–1026
 phosphatase 50
 plasmablast 542
 poorly differentiated neoplasms 764
 portal vein drainage 1326
 portal vein resection 1049, 1288
 portal vein thrombosis 516, 518, 519
 positron emission tomography (PET) 1021–1026
 postprocedural pancreatitis 1265, 1267, 1268
 post-splenectomy sepsis 517
 precision medicine 317–320, 322, 323, 939, 1188–1193
 precursor lesions 969–978
 prediction 170
 premature zymogen activation 157, 161
 prevalence, chronic pancreatitis 405
 primary hyperparathyroidism 199
 prognosis 176–181
 prognostic factor 812, 1284, 1286
 protein synthesis 75–81
 proton therapy 1153, 1159–1160
PRSS1 378–379
 pseudoaneurysm 427
 pseudocysts 424–428, 486–492
 PTF1A 5, 6

q

quality of life 334, 338, 340, 341, 677, 710, 711

r

radiation therapy 1135, 1137, 1153–1161
 radical antegrade modular pancreatosplenectomy (RAMPS) 1064, 1065
 radiofrequency ablation (RFA) 829–831
 radionuclides 822, 824
 radiotherapy 1154, 1155, 1211, 1214, 1215
 randomized 1143–1150
 readmissions, acute pancreatitis 334–336
 recurrent acute pancreatitis 60, 319, 334–336
 regulation, duct cell 48–52
 relapse, autoimmune pancreatitis 609–612

relapse, type 2 autoimmune pancreatitis 557–558
 relief of pain 512
 re-resection 1211, 1213–1215
 resectability 1099–1102
 resectable 1131–1138
 resection margins 1109
 resection, nonfunctioning pancreatic neuroendocrine tumor 817–818
 respiratory failure 233
 respiratory insufficiency 232–234
 revised Atlanta classification (RAC) 170–174, 288, 289, 294
 Ricordi Chamber 517
 risk factors 481–484, 982–987
 rituximab 605–607, 609, 610
 robotic 1078, 1079, 1081, 1083, 1084, 1086, 1087, 1089
 robotic distal pancreatectomy (RDP) 1093–1097
 robotic pancreaticoduodenectomy 1093–1096
 robotic resection 1093–1097
 robotic surgery 523, 526–531, 693–698, 700–706, 1058–1060
 Rochelle 499

s

salvage completion pancreatectomy 1071, 1072, 1075
 SBRT 1153, 1154, 1156–1159, 1161
 secretin 65–66, 68–70
 secretinoma 876–878
 secretion, duct cell 48–53
 segmental resection 1281
 selective arterial calcium injection (SACI) test 868
 self-expandable lumen-apposing metal stents 285
 self-expandable metal stents 488
 sensory nerve 147–149
 serine protease inhibitor Kazal type 1 (SPINK1) 128–130, 379
 serotonin 66–68
 serous cyst adenoma (SCA) 631, 633–635, 642–644, 711, 715, 716, 962, 963
 serous cystic neoplasm (SCN) 617, 619, 620, 623–624, 639–640, 666–671, 724, 725
 serum markers 568–570
 severe acute pancreatitis 208–219, 284–286, 294, 296
 severe necrotizing pancreatitis 302, 303
 severity classification systems, acute pancreatitis 170–174

severity stratification 176, 180, 181
 shock 230, 232, 234
 Shwachman-Bodian-Diamond syndrome 27
 signaling pathways 4–7
 SILS 269
 SMAD4 912–914, 917
 small molecule inhibitors 1181, 1182, 1184
 small NF-pNETs 849, 850, 854
 smoking 107, 110–112, 396–401, 404, 408, 409, 899–902
 solid pseudopapillary neoplasm (SPN) 617, 620, 627–628, 633–634, 640–642, 648–649, 666–671, 693, 694, 963, 964
 solid pseudopapillary tumor of the pancreas (SPTP) 732–735
 somatostatin analogues (SSAs) 820–822, 868, 869
 somatostatinoma 876, 877, 880
 somatostatin receptor 872, 873
 somatostatin receptor scintigraphy (SRS) 794–796, 876
 sphincter of Oddi 56–62
 sphincter of Oddi dysfunction 60–62
 sphincterotomy 490
 SSRT 803
 staging 1109
 staging laparoscopy 1033–1035
 staging of advanced pancreatic cancer 1037–1043
 staging, PanNENs 891–893, 895
 steatorrhea 437–440
 stellate cells 19
 stem cell-derived islets 1311, 1318
 stent insertion 345, 347
 step-up approach 254–257, 289, 290, 301
 stereotactic body radiation therapy 1141–1142
 steroids 554, 556–558, 600–602, 609–611
 stratification, PanNENs 891, 892, 895
 stromal heterogeneity 1183
 stromal-tumor interactions 94
 substance P 148
 subtypes, molecular 934–939
 surgery, acute pancreatitis 244–250
 surgery, asymptomatic cystic neoplasm 674–678
 surgery, duodenal cancer 1281–1282
 surgery, pancreatic fistulas 300–303
 surgery, pancreatic resection 496, 497
 surgical bypass 1117–1120
 surgical complications 1222

surgical debridement 249–250
 surgical margin 1301
 surgical necrosectomy 256
 surgical palliation 1108, 1117–1120
 surgical procedures 469
 surveillance 811
 survival 341, 1143–1150, 1218–1225
 sweat chloride 392, 393
 sympathetic nervous system 69
 systemic inflammation 138, 140, 142
 systemic inflammatory response
 syndrome (SIRS) 155, 158, 159,
 230, 231, 233, 235
 systemic recurrence 1208, 1210,
 1211, 1213
 systemic therapy 1133, 1135–1137,
 1208, 1213, 1215
 systemic vein drainage 1326, 1327
 systems biology 323

t

targeted therapy 1180–1184, 1188,
 1191
 targeted treatment 821–823,
 829–831
 10-year outcomes, islet
 autotransplantation 519–520
 T follicular helper (Tfh) cells
 541, 542
 T helper 2 (Th2) cells 540–542
 therapy, autoimmune
 pancreatitis 609–611
 therapy, type 2 autoimmune
 pancreatitis 557–558
 thoracic duct 138–142
 three-dimensional imaging 1094
 tissue acquisition 367, 368, 372
 tissue dynamics 924
 tissue specification 4, 6, 7
 TNM staging and grading 756–758
 total pancreatectomy 1048, 1052,
 1071–1075
 total pancreatectomy with islet
 autotransplant (TPIAT) 516–520
 TP53 912–914
 transabdominal ultrasonography
 357–358
 transarterial chemoembolization
 (TACE) 829–831
 transarterial embolization (TAE)
 829–830
 transcription factors 5–7
 transcriptomics 936–939
 transgastric interventional endoscopic
 approach 488, 489
 transient receptor potential
 (TRP) 149–150
 treatment effect 1131–1138
 treatment, nonfunctioning pancreatic
 neuroendocrine tumor 817–819
 treatment, PanNENs 891–895,
 899–902
 treatment signatures 935
 trial 1143–1150
 TRIANGLE 1059
 tropical chronic pancreatitis
 (TCP) 383–386
 tropical pancreatitis 406
 tube feeding 431
 tumor-associated macrophages
 (TAMs) 942, 943, 945–946
 tumor microenvironment
 (TME) 942–948, 1164
 tumor necrosis factor alpha (TNF- α) 133
 Tumour-Node-Metastasis (TNM)
 staging system 754, 756–761
 25(OH)D 442, 443
 type 1 autoimmune pancreatitis
 (AIP) 535–538, 540–543, 546–552,
 561–565, 595, 597

type 2 autoimmune pancreatitis
 (AIP) 535–538, 543–544,
 546–551, 554–558, 561, 562, 564,
 565, 595, 597
 type 1 diabetes 1311

u

ulcerative colitis 543, 544
 unfolded protein response 78
 upfront surgery 1131, 1132, 1134

v

vagovagal reflex 65, 68, 69
 vascular invasion 1049–1050
 vascular resection 859, 1055, 1101
 vasoactive intestinal peptide-releasing
 (VIPomas) 876, 877, 879, 880
 venous thrombosis 427
 vertebrate pancreas 99–100
 video-assisted retroperitoneal
 debridement (VARD) 248, 250
 vitamin D 443
 vitamin deficiency 431

w

walled-off necrosis (WON) 209,
 211–214, 216, 217, 288–291
 walled-off pancreatic necrosis
 (WOPN) 260, 284–286,
 294–297
 “watch and wait” strategy 850, 851,
 854
 well-differentiated neoplasms 763,
 767
 Whipple procedure 1055–1060, 1093

z

Zollinger–Ellison syndrome 873
 zymogen production 28

